New Brain Stimulation Therapy Reports 68% PTSD Remission Rate in Clinical Trial

A newly cleared brain stimulation therapy could offer another treatment option for people living with post-traumatic stress disorder (PTSD). The approach uses information about each patient's brain activity to guide noninvasive magnetic stimulation, with preliminary clinical results suggesting substantial improvements in symptoms.

Developed by California-based Wave Neuroscience in collaboration with researchers at Texas A&M Health, Magnetic e-Resonance Therapy (MeRT) combines brainwave analysis with targeted magnetic pulses to address patterns of neural activity associated with PTSD. The company reports that the U.S. Food and Drug Administration (FDA) recently granted clearance for the device following an expedited review.

According to Wave Neuroscience, participants in its clinical trial experienced an average 52% reduction in PTSD symptoms, while 68% achieved remission. However, the complete peer-reviewed trial findings have not yet been published, making it difficult to independently assess the results or establish how the therapy compares with existing treatments.

Researchers involved in the project believe the findings could represent progress for patients who have not achieved sufficient relief through conventional care.

Why PTSD care needs new options

PTSD can develop after exposure to traumatic experiences, including military combat, serious accidents, physical or sexual assault, and natural disasters. Without effective treatment, symptoms may persist for years and significantly affect everyday functioning.

U.S. government estimates suggest that approximately 6% of Americans experience PTSD at some point in their lives. The condition is particularly relevant to military veterans and first responders, who may face repeated exposure to potentially traumatic events.

The mental health burden among veterans is substantial. Federal estimates indicate that approximately 17.5 veterans die by suicide each day, although suicide has multiple contributing factors and cannot be attributed to PTSD alone.

PTSD also frequently occurs alongside depression, substance misuse and chronic pain. Some patients undergo several courses of medication or psychotherapy without obtaining lasting relief.

Established treatments include trauma-focused psychotherapy and selective serotonin reuptake inhibitors (SSRIs), particularly sertraline and paroxetine.

A 2020 evidence review reported relatively modest average improvements on certain standardized symptom measures and remission rates below 15% in some treatment comparisons. However, outcomes vary considerably between therapies and studies, and these figures should not be interpreted as representing the effectiveness of all established PTSD treatments.

How the MeRT system works

MeRT builds on transcranial magnetic stimulation (TMS), a noninvasive procedure that uses a magnetic coil positioned against the scalp to deliver pulses that influence electrical activity in the brain.

TMS has already received FDA clearance for treatment-resistant depression and certain other psychiatric indications.

The MeRT approach adds detailed brainwave mapping and algorithm-assisted personalization.

Before treatment, patients undergo electroencephalography (EEG), which records electrical activity from different areas of the brain.

The resulting measurements are processed using a multivariate algorithm designed to identify patterns of neural activity that may be associated with PTSD symptoms.

Clinicians then use this information to develop an individualized stimulation protocol intended to target particular brain circuits rather than applying the same settings to every patient.

Treatment generally consists of five short sessions each week over approximately five to six weeks.

Researchers involved in the trial report that some participants maintained improvements after completing the active treatment period, although longer-term outcomes require further evaluation.

A precision medicine approach to the brain

Kenneth S. Ramos, a physician-scientist at Texas A&M and a specialist in precision medicine, helped guide the project's scientific strategy.

He argues that psychiatric treatment has historically been less individualized than care in some other medical specialties, despite growing evidence that biological differences can influence how patients respond to treatment.

Conventional TMS protocols generally stimulate predetermined brain regions using standardized treatment schedules.

MeRT instead attempts to identify patterns of neural activity that appear poorly coordinated and adjust stimulation parameters to the individual patient's electrophysiological measurements.

The approach is intended to influence the timing and activity of targeted neural circuits.

Ramos compares the distinction to repairing a leaking roof. A conventional approach might involve placing a tarp over the damaged area to reduce the immediate consequences, while personalized treatment seeks to identify and address the underlying source of the problem.

The analogy reflects the researchers' goal of moving beyond symptom management toward interventions guided by measurable biological characteristics.

However, whether EEG-guided personalization produces better outcomes than conventional TMS protocols remains an important question for future comparative research.

From breakthrough status to FDA clearance

The MeRT system received the FDA's Breakthrough Device designation in 2024.

This program is intended to accelerate the development and regulatory review of certain medical devices addressing serious conditions for which additional treatment options are needed.

Breakthrough designation allows more intensive interaction with regulators but does not itself constitute marketing authorization or eliminate applicable safety and effectiveness requirements.

According to the project team, Wave Neuroscience and Texas A&M moved the technology from early development to regulatory clearance in slightly more than two years.

The researchers attribute this relatively rapid progress to existing knowledge about TMS, a focused clinical development strategy and regulatory planning.

Rick Silva, a physician-researcher who led clinical trial oversight at Texas A&M, noted that medical device development can sometimes take nearly a decade.

He described the PTSD project as particularly meaningful because of its potential to help patients who have struggled to find effective treatment.

A new non-drug option for PTSD

Psychiatrist and PTSD specialist Israel Liberzon, the study's lead clinical investigator, describes MeRT as the first FDA-cleared nonmedication treatment specifically indicated for PTSD.

He views the technology as a potential addition to established therapies rather than a replacement for psychotherapy or medication.

Currently, sertraline and paroxetine are the two medications with explicit FDA approval for PTSD.

Evidence-based psychotherapies, including cognitive processing therapy and prolonged exposure therapy, can also provide substantial benefits.

However, these approaches often require sustained participation, and some patients find trauma-focused sessions emotionally demanding or discontinue treatment before completing a full course.

For individuals who experience troublesome medication side effects or have difficulty engaging with existing treatments, personalized brain stimulation could offer another option.

The preliminary trial findings suggest that the procedure was generally well tolerated, and many participants were able to continue their usual activities during treatment.

Nevertheless, the absence of fully published peer-reviewed results limits independent assessment of its effectiveness, safety and durability.

Potential to reshape mental healthcare

Leslie S. Prichep, chief scientific officer at Wave Neuroscience, says the development reflects decades of research into using electrophysiological biomarkers to guide psychiatric interventions.

The broader goal is to make mental healthcare more individualized, similar to medical specialties in which diagnostic measurements routinely help determine treatment choices.

Company representatives also believe that showing patients measurable patterns of brain activity could help reduce stigma surrounding PTSD.

They argue that presenting the condition in biological terms may help patients and families understand that trauma-related symptoms are not signs of personal weakness.

Researchers are also investigating whether personalized stimulation approaches could eventually benefit people with major depressive disorder, generalized anxiety disorder or traumatic brain injury.

However, each additional clinical indication would require its own supporting evidence and appropriate regulatory review.

Access and affordability remain important obstacles.

Wave Neuroscience and Texas A&M report that they are working with insurers, healthcare systems and veteran organizations to expand coverage and make the treatment available in more clinical settings.

Their long-term objective is to move individualized neuromodulation beyond specialized centers and into broader mental healthcare.

The project has particular significance at Texas A&M because of the university's longstanding connections with military and veteran communities.

Researchers involved in the work hope that more precisely targeted brain stimulation may eventually provide sustained relief for people living with the effects of trauma, including those who have not responded adequately to established treatments.

For now, the reported remission rate is encouraging, but independent publication of the clinical trial data and further research will be essential to determine how MeRT should fit into routine PTSD care.